Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
Cancer Medicine
|
May 31, 2019
Response to pneumococcal vaccination in multiple myeloma
Loïc Renaud, Susanna Schraen, Guillemette Fouquet, et al.
British Journal of Haematology
|
January 6, 2025
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
Cyrille Touzeau, Xavier Leleu, Mourad Tiab, et al.
Bone Marrow Transplantation
|
May 25, 2020
Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma
Zoé Van de Wyngaert, Virginie Nerich, Guillemette Fouquet, et al.
American Journal of Hematology
|
October 26, 2018
Carfilzomib weekly 20/56 mg/m<sup>2</sup> , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma
Valentine Richez, Cecile Gruchet, Stephanie Guidez, et al.
Clinical Hematology International
|
June 1, 2026
Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France
Decaux Olivier, Ronan Garlantezec, Aurore Perrot, et al.
Haematologica
|
November 21, 2024
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program
Aurore Perrot, Cyrille Hulin, Ariane Boumendil, et al.
Blood Cancer Journal
|
October 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
Philippe Moreau, Cyrille Hulin, Alexis Talbot, et al.
Haematologica
|
November 14, 2024
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study
Arthur Bobin, Salomon Manier, Joe De Keizer, et al.
Leukemia
|
October 15, 2021
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
Arthur Bobin, Maéva Kyheng, Stéphanie Guidez, et al.
Haematologica
|
April 20, 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
Alexis Talbot, Arthur Bobin, Léa Tabone, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
Cancer Medicine
|
May 31, 2019
Response to pneumococcal vaccination in multiple myeloma
Loïc Renaud, Susanna Schraen, Guillemette Fouquet, et al.
British Journal of Haematology
|
January 6, 2025
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
Cyrille Touzeau, Xavier Leleu, Mourad Tiab, et al.
Bone Marrow Transplantation
|
May 25, 2020
Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma
Zoé Van de Wyngaert, Virginie Nerich, Guillemette Fouquet, et al.
American Journal of Hematology
|
October 26, 2018
Carfilzomib weekly 20/56 mg/m<sup>2</sup> , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma
Valentine Richez, Cecile Gruchet, Stephanie Guidez, et al.
Clinical Hematology International
|
June 1, 2026
Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France
Decaux Olivier, Ronan Garlantezec, Aurore Perrot, et al.
Haematologica
|
November 21, 2024
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program
Aurore Perrot, Cyrille Hulin, Ariane Boumendil, et al.
Blood Cancer Journal
|
October 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
Philippe Moreau, Cyrille Hulin, Alexis Talbot, et al.
Haematologica
|
November 14, 2024
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study
Arthur Bobin, Salomon Manier, Joe De Keizer, et al.
Leukemia
|
October 15, 2021
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
Arthur Bobin, Maéva Kyheng, Stéphanie Guidez, et al.
Haematologica
|
April 20, 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
Alexis Talbot, Arthur Bobin, Léa Tabone, et al.
Page
of 5